Public Citizen: FDA's Approval of COVID-19 Treatment Should Be Promptly Revisited in Consultation With Outside Experts
April 22, 2021
April 22, 2021
WASHINGTON, April 22 -- Public Citizen issued the following news release on April 21, 2021:
The U.S. Food and Drug Administration (FDA) should promptly convene an external expert advisory panel to evaluate whether the approval of the antiviral COVID-19 treatment remdesivir should be rescinded, Public Citizen said today in a letter to the agency.
"The FDA's previous failure to convene its own public advisory committee to consider whether to approve remdesivir w . . .
The U.S. Food and Drug Administration (FDA) should promptly convene an external expert advisory panel to evaluate whether the approval of the antiviral COVID-19 treatment remdesivir should be rescinded, Public Citizen said today in a letter to the agency.
"The FDA's previous failure to convene its own public advisory committee to consider whether to approve remdesivir w . . .